Blog « 4/11 « Myriad RBM
 
  • Subscribe to our Blog

  • Categories

  •  

    Blood-based Biomarkers of Alzheimer’s disease

    As we continue to develop a better understanding of the underlying biology for neurological diseases such as Alzheimer’s, researchers are seeking biomarkers that may help in numerous ways. From early diagnosis or disease progression, to surrogate efficacy markers for treatments, biomarkers may be the key to better studying these diseases. The challenge is determining which […]

    » Read this post


    Cancer Biomarkers – Historically undervalued but it’s time for a change

    Tumor-Biomarker Diagnostics: More and more experts are realizing the value of biomarkers in cancer research, not only to monitor tumor progression, but also to guide the treatment of patients.  Understanding these factors has the potential to save tremendous amounts of money for researchers in clinical trials and could even influence insurance reimbursement plans for those […]

    » Read this post


    Markers of Neurodegeneration in Multiple Sclerosis

    A recent study has identified the increased presence of neurofilament subunits (NFL) in the serum and cerebrospinal fluid of patients with multiple sclerosis (MS). The research, published in the Journal of Neuroimmunology, suggests that NFL may induce an immune response and represent and early marker of axonal damage. The results support many previous findings that […]

    » Read this post


    Evidence Supporting another Amyloid Biomarker of Alzheimer’s

    Researchers at the UC Davis Alzheimer’s Disease Center have identified the protein amylin as another possible biomarker of AD. Amylin is a protein that is related to amyloid beta, a known marker of AD. Build up of amylin oligomers in patients at risk for diabetes creates a cytotoxic environment which damages the cells in the […]

    » Read this post


    How to use multiplexed immunoassays in inflammatory diseases

    Chronic inflammatory processes are associated with a remarkable range of human diseases including numerous cardiovascular, pulmonary, neurodegenerative, and autoimmune disorders. Advances in our understanding of inflammatory biomarkers and their role in disease offer tremendous clinical value. Myriad RBM’s multi-analyte profiling (MAP) technology provides comprehensive, quantitative and sensitive measurement of dozens of protein biomarkers involved in […]

    » Read this post


    Biomarker Reliability and Disease Characteristics

    Proper study design is one of the most important aspects of successful biomarker discovery and that includes both a thorough understanding of the disease population and which statistical tools to use. New research from Arizona State University examines how the predictive reliability of statistical tests relies not only on the choice of the test (clearly) […]

    » Read this post


    Swedish universities identify a prognostic protein biomarker for bladder cancer

    Research published in the British Journal of Cancer correlates membranous expression of PODXL in urothelial bladder cancer with unfavorable tumor characteristics. The marker demonstrates potential clinical utility for improved treatment stratification of patients.

    » Read this post


    Blood Protein May Contribute to Early Development of Atherosclerosis

    A study conducted by Dr. Eric Thorin of the Montreal Heart Institute, suggests blood levels of angiopoietin-like protein 2 (angptl2) may represent an early biomarker for atherosclerosis. Researchers discovered levels of angptl2 are six times higher in mice with coronary heart disease than in healthy mice. Their study also revealed angptl2 levels increase with age […]

    » Read this post


    Webinar: Translating Preclinical Pharmacology in Clinical Activity

    Download this webinar to learn how Myriad RBM’s products and services were used by VentiRx to compare potency, define PK/PD relationships, identify potential clinical biomarkers of VTX-2337 activity and establish a Minimal Anticipated Biological Effect Level (MABEL) for the initial clinical trial.

    » Read this post


    T-DM1 Most Effective for Aggressive HER2-Positive Breast Cancer

    A study presented at this month’s American Association for Cancer Research annual meeting by Jose Baselga, M.D., Ph.D., suggests that tumor levels of HER2 may determine the patient’s response to treatment with T-DM1. Patients with tumors expressing higher levels of HER2 gained greater benefits from T-DM1 compared to patients with tumors expressing lower levels of […]

    » Read this post